ReviewPediatric research2026
Current concepts and challenges in pediatric diastolic dysfunction and heart failure with preserved ejection fraction.
Review in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Heart failure with preserved ejection fraction (HFpEF) has transitioned from an underrecognized and poorly characterized condition to a recognized, increasingly prevalent form of heart failure in the adult population, accounting for approximately half of all heart failure cases. Improved diagnostic capabilities and the growing burden of risk factors, including aging, hypertension, diabetes, and obesity, drive this rise. In contrast, pediatric HFpEF remains largely under-characterized, arising in a heterogeneous context that includes congenital heart disease and restrictive cardiomyopathies. The true incidence and prevalence of pediatric HFpEF remain difficult to establish due to challenges such as the absence of standardized diagnostic criteria, limited sensitivity of conventional diastolic function parameters, a lack of age-specific reference ranges for imaging and biomarker thresholds, and nonspecific symptoms that complicate early detection. While recent pharmacological advances in adult HFpEF, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists, have demonstrated incremental benefits, there is a notable absence of evidence-based treatments for pediatric HFpEF. This review provides an up-to-date overview of pediatric HFpEF, highlighting key diagnostic challenges and therapeutic gaps, discussing recent advancements in diagnostics and emerging therapeutic strategies with potential relevance for pediatric care. IMPACT: This article addresses pediatric heart failure with preserved ejection fraction (HFpEF), a condition that is emerging in the pediatric population. While HFpEF is a well-established and prevalent condition in adults, its prevalence in children remains underrecognized and poorly understood. This article highlights key challenges in diagnosing and managing pediatric HFpEF, including the absence of standardized diagnostic criteria, limited sensitivity of traditional diastolic function measures, and a lack of age-specific imaging biomarkers. In this up-to-date review, we discuss those limitations, emphasizing the need for greater research into its pathophysiology and therapeutic strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.